Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Risk factors for high-grade prostate cancer in an inner-city population: Analysis of commonly dispensed medications and patient comorbidities.

David Musheyev, Yusuf Sevencan, Eli Berglas et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17080

e17080 Background: The purpose of this study was to determine risk factors for having high-grade prostate cancer at biopsy by analyzing commonly dispensed...

Real-world zanubrutinib treatment patterns in mantle cell lymphoma (MCL) among US community oncology patients with prior Bruton tyrosine kinase inhibitor (BTKi) therapy.

Rushir J. Choksi, Gregory A. Maglinte, Xiaoliang Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23270

e23270 Background: MCL is a rare and aggressive type of non-Hodgkin lymphoma. The next-generation BTKi, zanubrutinib (zanu), was developed to maximize eff...

Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial.

Jingjing Miao, Runda Huang, Lin Wang et al. Jun 01, 2025 pp. 6040-6040 10.1200/jco.2025.43.16_suppl.6040

6040 Background: The PRANCIS model has been shown to be robust for identifying patients with recurrent nasopharyngeal carcinoma (rNPC) who are at high ris...

Temporal patterns in renal cancer mortality: A 20-year analysis of US-Mexico border states.

Rajiv Doddamani, Manas Pustake, Mohammad Arfat Ganiyani et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16534

e16534 Background: Kidney cancers pose a growing health challenge in the U.S., with rising incidence and mortality. Individuals in U.S.-Mexico border stat...

First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.

Guang-Hai Dai, Ru Jia, Hai-Yan Si et al. Jun 01, 2025 pp. 4161-4161 10.1200/jco.2025.43.16_suppl.4161

4161 Background: PDAC is a highly aggressive cancer with limited treatment options. Previous reports of NCT05218889 showed promising efficacy of nab-Pacli...

Predicting pathologic complete response in colorectal cancer patients after immunotherapy based on endoscopic biopsy and deep learning approach.

Chaoyuan Xiao, Hai-Ning Chen, Weijiu Zhang Jun 01, 2025 pp. 3532-3532 10.1200/jco.2025.43.16_suppl.3532

3532 Background: Immune checkpoint inhibitors (ICIs) have emerged as effective treatments for microsatellite instability-high (MSI-H)/deficient mismatch r...

Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses.

Cong Sun, Hengqi Liu, Ningning Zhang et al. Jun 01, 2025 pp. 7002-7002 10.1200/jco.2025.43.16_suppl.7002

7002 Background: The 2022 World Health Organization Classification of Hematologic Malignancies classifies follicular lymphoma grad...

Immune landscape of sarcoma patients treated with an autologous dendritic cell vaccine.

Aditi Dhir, Shannon Saigh, Eric Wieder et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23530

e23530 Background: The role of the sarcoma immune tumor microenvironment (TME) is a critical area of ongoing research, particularly to understand response...

Return to intended oncologic therapy in patients with metastatic non-small cell lung cancer discharged to a skilled nursing facility.

Anirudh Yalamanchali, Preeyal Patel, Ali Mushtaq et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23062

e23062 Background: Hospitalized patients with metastatic non-small cell lung cancer (mNSCLC) with poor performance status are commonly discharged to a ski...

Pathomics-based prediction of thymic epithelial tumor subtypes within the French RYTHMIC network.

Lodovica Zullo, Mathilde Bateson, Jose Carlos Benitez-Montanez et al. Jun 01, 2025 pp. 8112-8112 10.1200/jco.2025.43.16_suppl.8112

8112 Background: Thymic epithelial tumors (TETs) are classified into primary subtypes (A, AB, B1, B2, B3, C) and mixed classes, determined by varying prop...

Neo-adjuvant chemo-immunotherapy in pancreatic cancer: Results of the Australasian Gastrointestinal Trials Group (AGITG) NEO-IMPACT pilot trial.

Lorraine A. Chantrill, Jaswinder S. Samra, Niall C. Tebbutt et al. Jun 01, 2025 pp. 4189-4189 10.1200/jco.2025.43.16_suppl.4189

4189 Background: Despite curative intent surgery and peri-operative chemotherapy for resectable pancreatic ductal adenocarcinoma (PDAC), recurrence rate r...

Investigation of tumor-associated macrophages (TAMs) and therapeutic resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).

Soki Kashima, Rishabh Rout, Miya Hugaboom et al. Jun 01, 2025 pp. 4527-4527 10.1200/jco.2025.43.16_suppl.4527

4527 Background: RCC is characterized by a tumor microenvironment (TME) enriched in TAMs, which suppress antitumor immunity in RCC. We conducted a compreh...

Bothersome hot flashes following relugolix and stereotactic body radiotherapy for localized prostate cancer.

Sukhjeevan Nijhar, Sarthak Shah, Srinivas Sowmiyanarayanan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17087

e17087 Background: Androgen deprivation therapy (ADT) has been shown to improve cancer control when combined with radiation therapy. Relugolix is an oral...

Disparities in receipt of palliative interventions across disaggregated Hispanic subgroups with late-stage colon cancer in the United States.

Coby Garcia, Cody Chou, Khushi Kohli et al. Jun 01, 2025 pp. 12078-12078 10.1200/jco.2025.43.16_suppl.12078

12078 Background: Palliative interventions, defined as cancer-directed therapies with palliative intent, improve the quality of life and alleviate sufferi...

CDK inhibitors and radiation therapy in breast cancer: Hematologic toxicity and survival implications.

Omer Fatih Olmez, Selma Gürüf Avcı Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15095

e15095 Background: Breast cancer is the most common cancer and the second leading cause of cancer-related deaths in women. Hormone receptor-positive, HER2...

Identification of germline hereditary cancer syndrome variants and associated cancers in a healthcare biobank population.

Juliann Savatt, Melissa A. Kelly, Miranda Hallquist et al. Jun 01, 2025 pp. 10581-10581 10.1200/jco.2025.43.16_suppl.10581

10581 Background: Identification of pathogenic/likely pathogenic variants (P/LPV) in hereditary cancer syndrome (HCS) genes enables surveillance and preve...

MRI-based radiomics for prediction of isocitrate dehydrogenase subtype in glioblastoma multiforme through artificial intelligence models: A systematic review and meta analysis.

Sonali Belankar, Sravani Bhavanam, Ananya Prasad et al. Jun 01, 2025 pp. 2074-2074 10.1200/jco.2025.43.16_suppl.2074

2074 Background: Gliomas are aggressive tumours with poor prognosis. Isocitrate Dehydrogenase (IDH) mutations are present...

Patient preferences for survivorship educational programs.

Smriti Nair, Trishya Srinivasan, Deidre Geroni et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13870

e13870 Background: Patient feedback is instrumental in shaping the programs provided to a survivorship program. This valuable information allows us to mor...

Molecular profiling in targeted therapy of gliomas in a community setting.

Anastasia Vernadou, Eirini Papadopoulou, Stefanos V. Labropoulos et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14030

e14030 Background: In the 2021 WHO Classification for gliomas, molecular characteristics are mandatory for classification. However, there is not enough da...

Bone marrow polyclonal plasma cells in myeloma post-treatment: Implications on outcome and effect of therapy.

Miranda Lin, Dragan Jevremovic, Prashant Kapoor et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19531

e19531 Background: Effective treatment and elimination of clonal plasma cells (PC) in multiple myeloma (MM) are typically associated with recovery of poly...

Real-world efficacy of first-line chemotherapy plus nivolumab in gastric and GEJ adenocarcinoma patients: The ORACLE study.

Dario Spanu, Pina Ziranu, Gianmarco Ricagno et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16087

e16087 Background: Nivolumab (NIV) plus chemotherapy (CHT) is the standard first-line treatment for advanced gastric and gastroesophageal junction (GEJ) a...

Impact of racial disparities on efficacy and safety outcomes for patients with RRMM receiving T-cell engagers.

Lindsay Fogel, Jaeil Ahn, Adolfo Aleman et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19523

e19523 Background: The approval of T-cell engagers (TCEs) for multiple myeloma (MM) has led to prolonged survival, yet baseline health disparities have be...

Impact of mutant STK11, KEAP1, and KRAS on firstline chemoimmunotherapy survival outcomes in metastatic non-small cell lung cancer (NSCLC): A meta-analysis of randomized and comparative studies.

Suvarna Guvvala, Ankita Gupta, Sireesha Vutukuri et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20504

e20504 Background: Frontline chemoimmunotherapy has emerged as a revolutionary treatment modality for advanced lung cancer, significantly altering the the...

Endotrophin: Analysis of a fibroinflammatory biomarker during breast cancer therapy.

Bethania Santos, Dawei Bu, Ethan Johnson et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15056

e15056 Background: A major challenge in breast cancer research is identifying actionable biomarkers that enable the precise molecular characterization of...

Pan-cancer gene set discovery via scRNA-seq for optimal deep learning based downstream tasks.

Jong Hyun Kim, Yeonuk Jeong, Hj Yeo et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13606

e13606 Background: The application of deep learning to transcriptomics data has enabled various downstream tasks in cancer research. Due to the high dimen...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page